Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The physiological role of GH in the adult skeleton is unknown.

Who Took Part

The abstract describes 12 adults taking part.

The age groups tagged for this paper are teenagers and adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The adults were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the adults and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some adults received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

Topics PubMed links to this paper include Adipose Tissue, Bone Density, Growth Hormone, Muscles, Recombinant Proteins, Spine and Thigh.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 12 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1993 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.